Soleno Therapeutics: A Transformational 2025 Ahead?

Soleno Therapeutics (SLNO) stock jumped 9% after management described 2025 as a transformational year, citing early VYKAT XR revenue, upcoming full financial results, and a busy investor conference schedule. Despite the recent 9.75% 1-day share price return, the stock has experienced a 10.28% 30-day and 33.72% 90-day decline. Soleno remains loss-making with $98.675 million in revenue and trades at a large discount to the average analyst price target, raising questions about whether it is a mispriced rare disease story or if future growth is already reflected in the valuation.